The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...
Add Yahoo as a preferred source to see more of our stories on Google. Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show ...
Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company ...
In a startling reversal, Cambridge biotech Amylyx Pharmaceuticals, which won approval of a controversial and costly drug for amyotrophic lateral sclerosis in 2022, said Friday that its treatment ...
Shares of Amylyx Pharmaceuticals Inc. AMLX dropped more than 80% premarket on Friday after the company said its ALS treatment Relyvrio failed a phase 3 trial and that it may voluntarily withdraw the ...
March 19 (Reuters) - Seelos Therapeutics' (SEEL.O), opens new tab experimental ALS drug did not meet the main goal of a mid-stage trial, the company said on Tuesday, the latest study setback in a ...
Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show significant benefit in a large clinical trial and may be withdrawn from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results